Vitenskapelig artikkel

• Grønberg, Bjørn Henning; Killingberg, Kristin Toftaker; Fløtten, Øystein et al. (2025). High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial. (ekstern lenke)
• Kommedal, Øyvind; Eagan, Tomas Mikal Lind; Fløtten, Øystein et al. (2024). Microbiological diagnosis of pleural infections: a comparative evaluation of a novel syndromic real-time PCR panel. (ekstern lenke)
• Schaufel, Margrethe Aase; Gärtner, Fabian; Brekke, Jorunn et al. (2024). En kvinne i 30-årene med forvirring. (ekstern lenke)
• Dyrhovden, Ruben; Eagan, Tomas Mikal Lind; Fløtten, Øystein et al. (2023). Pleural Empyema Caused by Streptococcus intermedius and Fusobacterium nucleatum: A Distinct Entity of Pleural Infections. (ekstern lenke)
• Orstad, Silje; Fløtten, Øystein; Madebo, Tesfaye et al. (2023). “The challenge is the complexity” – A qualitative study about decision-making in advanced lung cancer treatment. (ekstern lenke)
• Kristensen, Are Korsnes; Grønberg, Bjørn Henning; Fløtten, Øystein et al. (2022). Trajectory of health-related quality of life during the last year of life in patients with advanced non-small–cell lung cancer. (ekstern lenke)
• Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien; Fløtten, Øystein et al. (2022). Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. (ekstern lenke)
• Grønberg, Bjørn Henning; Killingberg, Kristin Toftaker; Fløtten, Øystein et al. (2021). High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. (ekstern lenke)
• Halvorsen, Tarje Onsøien; Stokke, Kristin; Killingberg, Kristin Toftaker et al. (2020). Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. (ekstern lenke)
• Grønberg, Bjørn Henning; Sjøblom, Bjørg; Wentzel-Larsen, Tore et al. (2018). A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer. (ekstern lenke)
• Kristensen, Are Korsnes; Solheim, Tora Skeidsvoll; Fløtten, Øystein et al. (2018). Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials. (ekstern lenke)
• Valan, Christine Damgaard; Slagsvold, Jens Erik; Halvorsen, Tarje Onsøien et al. (2018). Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement. (ekstern lenke)
• Sjøblom, Bjørg; Saltyte Benth, Jurate; Grønberg, Bjørn Henning et al. (2017). Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer. (ekstern lenke)
• Bye, Asta; Sjøblom, Bjørg; Wentzel-Larsen, Tore et al. (2017). Muscle mass and association to quality of life in non-small cell lung cancer patients. (ekstern lenke)
• Halvorsen, Tarje Onsøien; Sundstrøm, Stein Harald; Fløtten, Øystein et al. (2016). Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer. (ekstern lenke)
• Sjøblom, Bjørg; Grønberg, Bjørn Henning; Wentzel-Larsen, Tore et al. (2016). Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. (ekstern lenke)
• Halvorsen, Tarje Onsøien; Herje, Martin; Levin, Nina et al. (2016). Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer. (ekstern lenke)
• Fløtten, Øystein; Grønberg, Bjørn Henning; Sundstrøm, Stein Harald et al. (2016). Oral versus intravenous vinorelbine in advanced NSCLC - a retrospective comparison. (ekstern lenke)
• Chatterjee, Manash; Turner, David C.; Felip, Enriqueta et al. (2016). Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. (ekstern lenke)
• Dønnem, Tom; Kilvær, Thomas Karsten; Andersen, Sigve et al. (2016). Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. (ekstern lenke)
• Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein et al. (2016). Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. (ekstern lenke)
• Sjøblom, Bjørg; Grønberg, Bjørn Henning; Saltyte Benth, Jurate et al. (2015). Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. (ekstern lenke)
• Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald et al. (2013). Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. (ekstern lenke)
• Fløtten, Øystein; Grønberg, Bjørn Henning; Bremnes, Roy M. et al. (2012). Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. (ekstern lenke)
• Grønberg, Bjørn Henning; Ciuleanu, Tudor; Fløtten, Øystein et al. (2012). A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. (ekstern lenke)
• Grønberg, Bjørn H.; Sundstrøm, Stein; Kaasa, Stein et al. (2010). Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. (ekstern lenke)
• Grønberg, BH; Bremnes, Roy M.; Aasebø, Ulf et al. (2009). A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. (ekstern lenke)

Sammendrag/abstract

• Grønberg, Bjørn Henning; Killingberg, Kristin Toftaker; Fløtten, Øystein et al. (2023). Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC). (ekstern lenke)
• Grønberg, Bjørn Henning; Levin, Nina; Sundstrøm, Stein Harald et al. (2015). Reduction in tumor size after the first course of cisplatin/etoposide (PE) in limited disease small-cell lung cancer (LD SCLC).. (ekstern lenke)
• Valan, Christine Damgaard; Halvorsen, Tarje Onsøien; Levin, Nina et al. (2015). Survival of patients with N3 lymph node disease in a cohort with limited disease small-cell lung cancer receiving concurrent chemoradiotherapy. (ekstern lenke)
• Grønberg, Bjørn Henning; Sundstrøm, Stein Harald; Fløtten, Øystein et al. (2015). Associations between Comorbidity, Treatment Toxicity and Overall Survival in Limited Disease Small-Cell Lung Cancer (LD-SCLC). (ekstern lenke)
• Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein et al. (2012). Randomized phase II trial comparing two schedules of thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC). (ekstern lenke)
• Grønberg, Bjørn Henning; Ciuleanu, Tudor; Fløtten, Øystein et al. (2011). Randomized Phase Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer: The MENZA Study. (ekstern lenke)

Brev til redaktøren

• Gärtner, Fabian; Assmus, Jörg; Fløtten, Øystein et al. (2022). Characteristics and survival of patients with non-small cell lung cancer treated with immune-checkpoint inhibitors in the real-world: experiences from Bergen, Norway. (ekstern lenke)

Doktorgradsavhandling

• Fløtten, Øystein; von Plessen, Christian (2019). Simplifying Treatment of Advanced Non-small Cell Lung Cancer. Regimen, Route of Administration, and Patients' Preferences . (ekstern lenke)

Poster

• Kristensen, Are Korsnes; Solheim, Tora Skeidsvoll; Fløtten, Øystein et al. (2018). Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small- cell lung cancer. (ekstern lenke)
• Grønberg, Bjørn Henning; Sundstrøm, Stein Harald; Fløtten, Øystein et al. (2015). Association between comorbidity, treatment toxicity and overall survival in limited disease small-cell lung cancer. (ekstern lenke)
• Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein et al. (2012). Phase II Trial Comparing Two Schedules of Thoracic Radiotherapy in Limited Disease Small-Cell Lung Cancer. (ekstern lenke)
• Grønberg, Bjørn Henning; Ciuleanu, Tudor; Fløtten, Øystein et al. (2011). Randomized Phase Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer: The MENZA Study. (ekstern lenke)
• Fløtten, Øystein; Bremnes, Roy M.; Grønberg, Bjørn Henning et al. (2010). Phase III study comparing vinorelbine-gemcitabine with vinorelbine-carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial. (ekstern lenke)
• Fløtten, Øystein; Bremnes, Roy M.; Grønberg, Bjørn Henning et al. (2010). Phase III study comparing vinorelbine-gemcitabine with vinorelbine-carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial. (ekstern lenke)

Vitenskapelig oversiktsartikkel/review

• Pedersen, Jesper Holst; Sørensen, Jens Benn; Saghir, Zaigham et al. (2017). Implementation of lung cancer CT screening in the Nordic countries. (ekstern lenke)

Nettsider (opplysningsmateriale)

• Amundsen, Tore; Fløtten, Øystein; Bugge, Anders Standal et al. (2013). Nasjonal handlingsplan for lungekreft (for Helsedirektoratet, HD og Norwegian Lung Cancer Group, NLCG) - utredning og behandling (utredningskapittelet). (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin